OBJECTIVES: This study evaluates the ROI (return on investment) for a PCV13 vaccination with campaign by corporations for individuals who are 50+ years old. METHODS: A budget impact analysis was developed considering vaccination costs, pneumococcal disease events, and productivity loss from employee absence due to sickness or death. Clinical events were calculated using a Markov model with individual-level simulation considering a cohort of 1.000 employees and an annual discount rate of 5%.Only the portion of employees more than 50 years of age was considered.  (21% according to Brazilian Institute for Geography and Statistics, IBGE). Absence days due to health events were retrieved from national labor legislations. Average wage was retrieved from IBGE 2013. Return on Investment was calculated as the time until savings from the cost of productivity gains exceeds investment in a vaccination program. RESULTS: A campaign  for 206 employees 50+ years old cost BRL 31.724 and in the first 2 years the  return will be BRL 15.449 due to reduction in events and absenteeism  and  one fewer death. The ROI will be in 4,17 years. CONCLUSIONS: In addition to decreasing productivity loss, death, and additional treatment cost, a pneumococcal vaccination campaign for employees over 50 years old yields a positive return on investment.